EB1

Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and lisavanbulin at AACR Annual Meeting

Retrieved on: 
Wednesday, April 13, 2022
Tubulin, Cell proliferation, Infection, Isavuconazonium, EB1, Population, FGFR, Squamous cell carcinoma, Paclitaxel, Merck & Co., Research, Mycosis, Skin cancer, PD-L1, Human, Brain, Glioblastoma, Patient, ICCA, SIX Swiss Exchange, Merck, FGFR1, FGFR2, SAC, Communication, TTK, Maintenance, Roche, Colorectal cancer, Chromosome, PLK1, Neoplasm, Safety, Large-cell lung carcinoma, MCI, Epithelium, Cell division, Cancer, Breast, Cholangiocarcinoma, Medulloblastoma, Therapy, Mitosis, Targeted molecular therapy for neuroblastoma, Vaccine, Pharmaceutical industry, Medical imaging, EU, CSF1R

The compound is a unique dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1).

Key Points: 
  • The compound is a unique dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1).
  • Both kinases collaborate in activating the mitotic spindle assembly checkpoint (SAC), a cell division mechanism regulating correct chromosome alignment and segregation.
  • BAL0891 has shown anti-proliferative activity across diverse tumor cell lines in vitro and single agent efficacy in in-vivo models of solid human cancers.
  • Derazantinib, lisavanbulin and BAL0891 and their uses are investigational and have not been approved by a regulatory authority for any use.

Basilea to become a leading anti-infectives company backed by strong financial results 2021

Retrieved on: 
Tuesday, February 15, 2022
Cryptococcosis, New Drug Application, Patient, Aspergillosis, Webcast, CET, SIX Swiss Exchange, Food, Cancer, FGFR, Board of directors, CHF, Infection, Glioma, PFS, National Medical Products Administration, Center, DCR, Center for Drug Evaluation and Research, IND, FGFR2, NMPA, Adult, Mucormycosis, Acinetobacter baumannii, Isavuconazonium, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, EB1, Progression-free survival, Glioblastoma, SAB, PLK1, ICCA, DXR, TTK, Investigational New Drug, FDA, Population, Mycosis, Pfizer, Board, Communication, USD, Partnership, NDA, Research, MCI, ORR, Plasma protein binding, Pharmaceutical industry

The excellent commercial performance triggered several milestone payments from our partners with a total of approximately CHF 35 million in 2021.

Key Points: 
  • The excellent commercial performance triggered several milestone payments from our partners with a total of approximately CHF 35 million in 2021.
  • The first approval in December 2021 triggered a USD 10 million milestone payment to Basilea.
  • Basilea Pharmaceutica Ltd. will host a conference call and webcast today, Tuesday, February15, 2022, at 4 p.m. (CET), to discuss the Companys financial and operating results and to provide an outlook.
  • Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland.

Basilea announces submission of Investigational New Drug application for novel oncology drug candidate BAL0891

Retrieved on: 
Tuesday, November 16, 2021
Population, Safety, FGFR, Basilea Pharmaceutica, Bile duct, Maintenance, CSF1R, Cancer, PD-L1, Skin cancer, Breast, Medulloblastoma, SIX Swiss Exchange, Colorectal cancer, Drug discovery, Cell proliferation, EB1, Infection, IND, Merck, Roche, Food, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Cholangiocarcinoma, Squamous cell carcinoma, Human, Mycosis, FGFR2, Neoplasm, Tubulin, ICCA, Brain, Large-cell lung carcinoma, Therapy, Isavuconazonium, Targeted molecular therapy for neuroblastoma, ERCC excision repair 6 like, spindle assembly checkpoint helicase, FGFR1, Investigational New Drug, Communication, Paclitaxel, Patient, Merck & Co., Epithelium, Pharmaceutical industry, Medical imaging, Vaccine

If the IND is granted, Basilea plans to initiate a phase 1 study in patients with advanced solid tumors in the first quarter of 2022.

Key Points: 
  • If the IND is granted, Basilea plans to initiate a phase 1 study in patients with advanced solid tumors in the first quarter of 2022.
  • Submitting this IND is an important regulatory milestone for Basilea as we are moving closer to adding BAL0891 as the third oncology drug candidate to our clinical pipeline.
  • Basilea has filed an Investigational New Drug application to the U.S. Food and Drug Administration, with the goal to initiate first-in-human clinical studies in the first quarter of 2022.
  • Derazantinib and lisavanbulin and their uses are investigational and have not been approved by a regulatory authority for any use.

Basilea reports strong financial results for half-year 2021 with significantly increased cash flow from marketed brands and increases 2021 full-year guidance

Retrieved on: 
Tuesday, August 17, 2021
FDA Special Protocol Assessment, Cancer, PFS, Melanoma, Webcast, Human, Economic union, Glioblastoma, Progression-free survival, Program, Skin, Glioma, Trial of the century, Communication, Infection, CEST, TARGET, Research, EB1, Food, Mucormycosis, Marketing, NDA, SAB, Review, Acinetobacter baumannii, DXR, IND, Safety, ISIN, CHF, SIX Swiss Exchange, Patient, News, Investigational New Drug, ICCA, Partnership, FGFR, Staphylococcus, Breast, FGFR2, Eurasian Economic Union, Neoplasm, FDA, New Drug Application, Mycosis, USD, Medulloblastoma, Targeted molecular therapy for neuroblastoma, Initial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Animal

In April 2021, Basilea announced that it has completed the divestment of its Chinese research and development subsidiary to the U.S.-based custom manufacturing organization PHTInternationalInc.

Key Points: 
  • In April 2021, Basilea announced that it has completed the divestment of its Chinese research and development subsidiary to the U.S.-based custom manufacturing organization PHTInternationalInc.
  • In addition, Basilea is entitled to receive additional payments of USD 3.8 million (CHF 3.6 million) over the next three years.
  • Since the beginning of the year, Basilea reduced the convertible bond maturing in December 2022 (ISIN CH0305398148) by CHF 12.4 million.
  • Basilea Pharmaceutica Ltd. will host a conference call and webcast today, Tuesday, August17, 2021, at 4 p.m. (CEST), to discuss the Companys financial and operating results.